Karpova, D., Rettig, M.P., Ritchey, J., (…), Link, D.C., *DiPersio, J.F., The Journal of clinical investigation, 130, 2019.
Marín-Hernández, D., Iñiguez, L.P., Nixon, D.F., (…), *DiPersio, J.F., Ley, T.J., New England Journal of Medicine, 380(13), pp. 1289-1290, 2019.
Dr. John DiPersio (Department of Medicine, Chief, Division of Oncology) will lead the first US Phase I/II clinical trial for ApoGraf, a stem cell selection technology developed by Cellect Biotechnology. ApoGraf is designed to prevent acute Graft vs. Host Disease following bone marrow transplant.
Alahmari, B., Cooper, M., Ziga, E., (…), DiPersio, J.F., Choi, J. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. PLoS One, 13, p.e0207609, 2018.